 |
Prospector
Profile
07.1664
|
| |
| Forbes Medi-Tech, Inc. |
NAICS |
541710 |
| 200 – 750 West Pender Street
Vancouver, British Columbia, Canada V6C 2T8 |
Description |
Biotechnology |
| (604) 689-5899 |
Employees |
33 |
| http://www.forbesmedi.com/s/Home.asp |
Revenue |
CDN$(mil) |
7.2420 |
| |
Income |
CDN$(mil) |
-10.8440 |
| |
Assets |
CDN$(mil) |
25.3870 |
| |
Liability |
CDN$(mil) |
5.0370 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Forbes Medi-Tech, Inc. had a net loss of $3.1 million on revenues of $2.3 million for the third quarter ended September 30, 2007, which is lower than the $3.5 million net loss on revenues of $1.4 million reported during the third quarter of last year. For the nine months ended September 30, 2007, the Company had a $8.9 million net loss, much higher than the $6.1 million net loss incurred during the same period last year.
|
| |
|
Intellectual Property:
As of March 1, 2007, the Company holds rights to 191 patents and pending patent applications in the United States and worldwide, of which 17 are exclusively licensed from the University of British Columbia. Many of the 191 patents and patent applications are interrelated and in effect assert rights to substantially similar inventions in different jurisdictions. Some are patents granted across the European Patent Community and have been validated in 18 or more of the available jurisdictions. In the United States, the Company has 7 issued patents, and 34 pending patent applications. In addition to the United States, the Company has patents issued in China, Japan, Canada, Norway, Russia, South Africa, New Zealand and all countries of the European Patent Community. [SEC Filing 20-F 04-03-07]
|
| |
|
Description:
Forbes Medi-Tech is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of life-threatening disease.
|
| |
|
Officers:
Charles A. Butt (Pres. & CEO); Laura Wessman (SVP); David Goold (CFO); Dr. John Nestor (Chief Scientific Officer); Jeffrey J.E. Motley (VP); David Stewart (VP); Jerzy Zawistowski (VP)
|
| |
|
Auditor:
KPMG LLP
|
| |
|
Securities:
Common Stock-Symbol FMTI; Nasdaq;
38,402,100 common shares outstanding as of December 31, 2006.
|
| |
| |
| |
| return to main page |
|
|
